A Phase 1 interventional study of Tasimelteon and Active Control Placebo in Healthy Volunteers, sponsored by Vanda Pharmaceuticals. Completed at 1 site in Canada. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.
Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to investigate next-day residual effects of tasimelteon compared with placebo and active control in healthy subjects.
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
single dose
Drug: Tasimelteon · Drug: Active Control Placebo
single dose
Drug: Active Control Placebo · Drug: Tasimelteon Placebo
single dose
Drug: Tasimelteon Placebo · Drug: Active Control
oral capsule
oral capsule
oral capsule
oral capsule
Next-day effects on simulated driving performance as measured by changes in Standard Deviation of Lateral Position (SDLP)
Time frame: Day 1 of Treatment Period 1, Treatment Period 2, and Treatment Period 3 (each Period is 1 day, separated by washout)
Ran from Jul 2018 to primary completion in Aug 2018, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon